Neuriva $8 Million Deal Wrongly Approved, Appeals Court Told

A purported $8 million false-ad settlement with Neuriva brain pill maker Reckitt Benckiser LLC disproportionately benefits the plaintiffs’ attorneys, objector Theodore Frank told the Eleventh Circuit, urging it to scrap the deal.

David Williams and others alleged Reckitt Benckiser and RB Health (US) LLC deceptively touted the brain booster as “backed by science” and “clinically proven” to improve brain performance when there is no scientific or clinical proof it delivers any such benefit.

The settlement provides $8 million to pay claims as they’re made, allowing up to $65 each for class members with proof of purchase, and up to $20 ...